Advertisement

Topics

Verastem Oncology Company Profile

06:20 EDT 24th May 2018 | BioPortfolio

Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. Verastem Oncology is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in indolent Non-Hodgkin Lymphoma (iNHL) and a Phase 3 clinical trial in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Verastem Oncology’s New Drug Application (NDA) requesting the full approval of duvelisib for the treatment of patients with relapsed or refractory CLL/SLL, and accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma (FL) was accepted for filing by the U.S. Food and Drug Administration (FDA), granted Priority Review and assigned a target action date of October 5, 2018. In addition, Verastem Oncology is developing the FAK inhibitor defactinib, which is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic cancer, ovarian cancer, non-small-cell lung cancer (NSCLC), and mesothelioma. Verastem Oncology’s product candidates seek to treat cancer by modulating the local tumor microenvironment and enhancing anti-tumor immunity. For more information, please visit www.verastem.com.


News Articles [487 Associated News Articles listed on BioPortfolio]

Verastem gains priority review for novel oncology candidate in the USA

Shares in Verastem were lifted about 10% yesterday as the East Coast, USA-based biotech firm revealed…

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq: VSTM), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock o...

Public offering nets $24.6mm for Verastem

Oncology drug developer Verastem Inc. netted $24.6mm through a public sale of 8.4mm common shares at $2.97. Funds will support launch and commercialization costs of the company's lead blood cancer can...

Verastem to Present at the 30th Annual ROTH Conference

Verastem, Inc. (NASDAQ:VSTM), focused on developing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 30th...

At Verastem, Infinity’s Former Blood Cancer Drug Heads to FDA

Verastem has filed for FDA approval of duvelisib, a blood cancer drug the Needham, MA, company took a shot on in a 2016 bargain deal with Infinity Pharmaceuticals. Verastem will seek approval of duvel...

Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the grant of stock option...

Verastem seeks FDA approval for lymphoma drug candidate

Verastem filed a new-drug application seeking full approval from the FDA for duvelisib for the treatment of relapsed/refracto -More- 

FDA grants priority review for Verastem’s Duvelisib but toxicities weaken its prospects

The FDA has accepted a new drug application (NDA) for Verastem’s duvelisib, and earlier this week granted it priority review....Read More... The post FDA grants priority review for Verastem’s Duve...

PubMed Articles [1381 Associated PubMed Articles listed on BioPortfolio]

Nonspecialty Nurse Education: Evaluation of the Oncology Intensives Initiative, an Oncology Curriculum to Improve Patient Care.

A community hospital combined its medical and surgical patients with cancer on one unit, which resulted in nurses not trained in oncology caring for this patient population.

Biosimilars in oncology: much ado about nothing?

Medical physics in radiation Oncology: New challenges, needs and roles.

Oncology Nurse Generalist Competencies: Oncology Nursing Society's Initiative to Establish Best Practice.

A project team was formulated to create evidence-based oncology nurse generalist competencies (ONGCs) to establish best practices in competency development, including high-risk tasks, critical thinkin...

The use of antidepressants in oncology: a review and practical tips for oncologists.

The use of psychotropic drugs, namely those with an antidepressant profile (ADs), is a mandatory part of an integrated treatment of psychiatric disorders among cancer patients. We aimed to synthetize ...

Clinical Trials [476 Associated Clinical Trials listed on BioPortfolio]

Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System

The purpose of this study is to learn what cancer patients think about IBM Watson Oncology. IBM Watson Oncology is a computer program designed to help inform oncologists about the best che...

Support of the Sexual Health in Oncology

Implementation of sexual health support program in oncology department. This program is organized in 3 axes. One is to inform the side effects of treatment on sexual health. There is a co...

Clinical Concordance Study Between Watson for Oncology and Clinician Practice

At present, Watson for Oncology has been applied in 14 countries worldwide, including China, the United States, Holland, Thailand, India, Korea, Poland, Slovakia and Bangladesh. In a doubl...

Osteopathic Manipulative Treatment in Oncology Patients' Management

The aim of present study was to study the osteopathic manipulative effects on pain relief and quality of life improvement on hospitalized oncology geriatric patients. A non-randomized comp...

Survivorship Care Plans in a Community Oncology Practice

This is a two part observational study evaluating the feasibility of implementing an EHR-based model within a community oncology practice.

Companies [713 Associated Companies listed on BioPortfolio]

Verastem Oncology

Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and qualit...

Verastem, Inc. Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor ...

Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cell...

Takeda Oncology

Takeda Oncology, headquartered in Cambridge, MA, delivers novel medicines to patients with cancer worldwide through its commitment to science, breakthrough innovation and passion ...

OncLive

OncLive is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Contemporary O...

More Information about "Verastem Oncology" on BioPortfolio

We have published hundreds of Verastem Oncology news stories on BioPortfolio along with dozens of Verastem Oncology Clinical Trials and PubMed Articles about Verastem Oncology for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Verastem Oncology Companies in our database. You can also find out about relevant Verastem Oncology Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record